Natera on Thursday announced a new study within the Phase II I-SPY 2 trial that will evaluate the ability of its Signatera minimal residual disease test to monitor breast cancer patients' response to neoadjuvant therapy.

Researchers have determined that a liquid biopsy human papillomavirus DNA test may serve as a useful tool for the diagnosis and surveillance of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC).

Helio Genomics said Thursday that its sister company, Laboratory for Advanced Medicine & Health Group (LAMH), has received approval from the National Medical Products Administration (NMPA) in China for its cell-free DNA-based liver cancer detection test. The assay is the first of its kind to receive this approval.

South Korean liquid biopsy firm IMBdx said Thursday that it is expanding an ongoing collaboration with AstraZeneca under a project called PROSPER 2.0, which aims to improve access to targeted therapies for individuals with metastatic prostate cancer in markets outside the US.

Global life sciences company Labcorp has introduced a new liquid biopsy test called Labcorp Plasma Focus.

On May 8, Singlera Genomics announced that its self-developed PDACatch test, a novel DNA methylation-based liquid biopsy test for detecting pancreatic cancer in high-risk populations, has been granted Breakthrough Medical Device designation by FDA.

Quest Diagnostics and Haystack Oncology said Thursday that they have reached a definitive agreement for Quest to acquire Haystack for up to $450 million in cash.

UK circulating tumor cell firm Angle said Wednesday that it has signed an agreement with BioView to develop a liquid biopsy HER2 assay using its cell isolation technology, Parsortix, and BioView's automated microscopy systems and software.

Agena Bioscience and nRichDX said Friday that they have entered a commercial partnership to co-promote their products to researchers developing liquid biopsy applications on Agena's MassArray platform.

Stilla Technologies and Atila BioSystems said on Thursday that they will codevelop digital PCR kits for cancer liquid biopsy applications.